Quoin Pharmaceuticals Ltd   (QNRX)
Other Ticker:  
Price: $0.7410 $-0.03 -3.766%
Day's High: $0.795 Week Perf: -5.01 %
Day's Low: $ 0.74 30 Day Perf: -35 %
Volume (M): 91 52 Wk High: $ 12.00
Volume (M$): $ 67 52 Wk Avg: $3.23
Open: $0.78 52 Wk Low: $0.42

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd is a privately held, research-driven pharmaceutical company that specializes in the development and commercialization of innovative and affordable pharmaceutical products for the global market. The company is committed to creating high-quality and effective products that meet the needs of patients and healthcare professionals.

The company was founded in 2016 and is headquartered in Hyderabad, India. It has a team of experienced professionals who are dedicated to scientific research, clinical development, regulatory affairs, manufacturing, and commercialization. Quoin Pharmaceuticals focuses on developing drugs in a wide range of therapeutic areas, including oncology, pain management, dermatology, and neurology.

One of the main objectives of Quoin Pharmaceuticals is to improve patient outcomes, and the company does this by investing heavily in R&D. It has a state-of-the-art research facility that is equipped with cutting-edge technology and equipment, enabling it to discover new drugs, study their mechanisms of action, and develop effective treatment strategies.

The company has a strong focus on quality and compliance, and it strictly adheres to international standards and regulations. All its products are manufactured in certified facilities that meet the highest quality and safety standards.

Quoin Pharmaceuticals has an extensive global network of partners, including contract manufacturers, research institutions, and distribution companies. This enables the company to leverage its resources to deliver innovative drugs and cutting-edge healthcare solutions to markets around the world.

Quoin Pharmaceuticals has a strong commitment to sustainability and social responsibility. It recognizes the importance of giving back to the community, and it supports a range of initiatives in education, healthcare, and environmental conservation.

Overall, Quoin Pharmaceuticals is a dynamic and innovative pharmaceutical company that is dedicated to improving patient outcomes by developing safe, effective, and affordable drugs.

   Company Address: 42127 Pleasant Forest Court Ashburn 20148 VA
   Company Phone Number: 980-4182   Stock Exchange / Ticker: NASDAQ QNRX


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd Faces Stock Price Plunge in Fourth Quarter of 2023

Quoin Pharmaceuticals Ltd has recently experienced a significant decline in its stock price. Over the course of the last month, the stock has declined by -64.67%, bringing the share price down to -75.26% in the past 90 days. Currently, the stock is trading on the NASDAQ at a price that is -62.6% below its 52-week average.
One of the reasons for this decline in stock price can be attributed to the company's fourth quarter earnings report for 2023. During this period, Quoin Pharmaceuticals reported a shortfall per stock at $-5.22 per share, compared to $4.99 per share in the previous year's financial reporting period. This represents an increase in the company's shortfall, from $-1.95 per share in the preceding financial reporting period.

Management Announcement

Quoin Pharmaceuticals' Public Offering Raises Concerns as Company Records Negative ROI and Trails Behind Industry Peers in Financial Performance.

Published Tue, Mar 5 2024 1:01 PM UTC

Quoin Pharmaceuticals' Public Offering Raises Concerns about Company's Financial Health
ASHBURN, Va., March 05, 2024 - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the pricing of its public offering, raising approximately $6.5 million in gross proceeds. However, the financial performance of the specialty pharmaceutical company raises concerns about its long-term...

Clinical Study

FDA Approves Quoin Pharmaceuticals' Expansion of Netherton Syndrome Clinical Trials to Include Teenage Patients, Promising Expedited Recruitment and Enhanced Data Analysis

Published Mon, Mar 4 2024 1:01 PM UTC

FDA Grants Quoin Pharmaceuticals Clearance to Include Teen Patients in Ongoing Netherton Syndrome Clinical Trials: Potentially Expediting Recruitment and Enhancing Data AnalysisIn a significant development, Quoin Pharmaceuticals has received FDA clearance to enroll teenage patients in their ongoing clinical studies for the treatment of Netherton Syndrome. This regulatory app...

Quoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd Faces Intensified Deficit in First Quarter of 2023, with Substantial Losses Reported

Quoin Pharmaceuticals Ltd, a company operating in the Healthcare sector, recently reported its financial first-quarter results for 2023, which showed an increased loss per share of $-0.34. This is opposite to the same quarter the previous year, where the company had reported zero loss per share. In the previous quarter, Quoin Pharmaceuticals Ltd had reported a loss of $-0.01 per share.
During the financial first quarter in 2023, the company experienced a net loss of $-2.603 million, as opposed to zero gain in the same quarter of the preceding year. This has resulted in a cumulative net loss of $-24 million during the 12 months ending in the financial first quarter of 2023, which translates to a negative return on assets (ROA) of -206.92%.


Quoin Pharmaceuticals Ltd's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Quoin Pharmaceuticals Ltd does not provide revenue guidance.

Earnings Outlook
Quoin Pharmaceuticals Ltd does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com